DAWN - NASDAQ

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWNยทNASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN ยท NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $21.53

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$191.4M
+ Cash & Equivalents$197.1M
Firm Value$5.7M
- Debt$2.8M
Equity Value$2.9M
/ Shares Outstanding102,675,502B
DCF Value$0
OVERVALUED BY 100%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$73.0M
-$51.4M
-$36.1M
-$25.4M
-$17.9M
-$12.6M
-$8.9M
-$6.2M
-$4.4M
-$3.1M
Maintenance CapEx
-$45.0K
-$31.7K
-$22.3K
-$15.7K
-$11.0K
-$7.8K
-$5.5K
-$3.8K
-$2.7K
-$1.9K
Owner Earnings
-$73.0M
-$51.4M
-$36.2M
-$25.4M
-$17.9M
-$12.6M
-$8.9M
-$6.2M
-$4.4M
-$3.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$67.6M
-$44.1M
-$28.7M
-$18.7M
-$12.2M
-$7.9M
-$5.2M
-$3.4M
-$2.2M
-$1.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your DAWN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.